Trove
Sign In Sign Up

ePocrates, Inc.

Organization
Mentions
6
Relationships
1
Events
1
Documents
3
Also known as:
ePocrates
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
1 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
organization athenahealth
Acquisition
5
1
View
Date Event Type Description Location Actions
N/A N/A Acquisition of ePocrates by athenahealth N/A View

HOUSE_OVERSIGHT_024050.jpg

This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.

Investment memorandum / fund report
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024022.jpg

This document is page 11 of a confidential presentation (likely an investment prospectus for 'NLV-III') detailing the history and senior team of New Leaf Ventures. It features a timeline of funds raised from 1993 to 2007 under Sprout and New Leaf brands, totaling billions in capital. The page highlights the biography of Managing Director Philippe Chambon, detailing his history with Sprout, Boston Consulting Group, and Sandoz Pharmaceutical, as well as his numerous board memberships in the healthcare and biotech sectors. The document bears a House Oversight Committee control number.

Investment prospectus / private placement memorandum
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024102.jpg

This document is a confidential financial schedule for 'Sprout Capital IX, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It details realized and unrealized investments in numerous healthcare and biotechnology companies, listing vintage years, costs, realized values, and IRRs. The document bears a 'HOUSE_OVERSIGHT' footer, indicating it was part of a congressional investigation.

Financial record (investment portfolio summary)
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search